RUBICON2026-04-012026-06-30RUBICON2026-06-30RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors1RUBICON2026-06-30CompositionOfBoardOfDirectors1RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors2RUBICON2026-06-30CompositionOfBoardOfDirectors2RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors3RUBICON2026-06-30CompositionOfBoardOfDirectors3RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors4RUBICON2026-06-30CompositionOfBoardOfDirectors4RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors5RUBICON2026-06-30CompositionOfBoardOfDirectors5RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors6RUBICON2026-06-30CompositionOfBoardOfDirectors6RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors7RUBICON2026-06-30CompositionOfBoardOfDirectors7RUBICON2026-04-012026-06-30CompositionOfBoardOfDirectors8RUBICON2026-06-30CompositionOfBoardOfDirectors8RUBICON2026-04-012026-06-30CompositionOfCommittees14RUBICON2026-06-30CompositionOfCommittees14RUBICON2026-04-012026-06-30CompositionOfCommittees15RUBICON2026-06-30CompositionOfCommittees15RUBICON2026-04-012026-06-30CompositionOfCommittees16RUBICON2026-06-30CompositionOfCommittees16RUBICON2026-04-012026-06-30CompositionOfCommittees17RUBICON2026-06-30CompositionOfCommittees17RUBICON2026-04-012026-06-30CompositionOfCommittees41RUBICON2026-06-30CompositionOfCommittees41RUBICON2026-04-012026-06-30CompositionOfCommittees42RUBICON2026-06-30CompositionOfCommittees42RUBICON2026-04-012026-06-30CompositionOfCommittees43RUBICON2026-06-30CompositionOfCommittees43RUBICON2026-04-012026-06-30CompositionOfCommittees68RUBICON2026-06-30CompositionOfCommittees68RUBICON2026-04-012026-06-30CompositionOfCommittees69RUBICON2026-06-30CompositionOfCommittees69RUBICON2026-04-012026-06-30CompositionOfCommittees70RUBICON2026-06-30CompositionOfCommittees70RUBICON2026-04-012026-06-30CompositionOfCommittees71RUBICON2026-06-30CompositionOfCommittees71RUBICON2026-04-012026-06-30CompositionOfCommittees95RUBICON2026-06-30CompositionOfCommittees95RUBICON2026-04-012026-06-30CompositionOfCommittees96RUBICON2026-06-30CompositionOfCommittees96RUBICON2026-04-012026-06-30CompositionOfCommittees97RUBICON2026-06-30CompositionOfCommittees97RUBICON2026-04-012026-06-30CompositionOfCommittees122RUBICON2026-06-30CompositionOfCommittees122RUBICON2026-04-012026-06-30CompositionOfCommittees123RUBICON2026-06-30CompositionOfCommittees123RUBICON2026-04-012026-06-30CompositionOfCommittees124RUBICON2026-06-30CompositionOfCommittees124RUBICON2026-04-012026-06-30CompositionOfCommittees125RUBICON2026-06-30CompositionOfCommittees125RUBICON2026-06-30MeetingOfBoardOfDirectors1RUBICON2026-04-012026-06-30MeetingOfBoardOfDirectors1RUBICON2026-06-30MeetingOfBoardOfDirectors2RUBICON2026-04-012026-06-30MeetingOfBoardOfDirectors2RUBICON2026-06-30MeetingOfBoardOfDirectors3RUBICON2026-04-012026-06-30MeetingOfBoardOfDirectors3RUBICON2026-04-012026-06-30MeetingOfCommittees1RUBICON2026-06-30MeetingOfCommittees1RUBICON2026-04-012026-06-30MeetingOfCommittees2RUBICON2026-06-30MeetingOfCommittees2RUBICON2026-04-012026-06-30MeetingOfCommittees3RUBICON2026-06-30MeetingOfCommittees3RUBICON2026-04-012026-06-30MeetingOfCommittees4RUBICON2026-06-30MeetingOfCommittees4RUBICON2026-04-012026-06-30MeetingOfCommittees5RUBICON2026-06-30MeetingOfCommittees5RUBICON2026-04-012026-06-30MeetingOfCommittees6RUBICON2026-06-30MeetingOfCommittees6RUBICON2026-03-31RUBICON2026-06-30UnlistedCompanyDomain1RUBICON2026-04-012026-06-30UnlistedCompanyDomain1RUBICON2026-03-31UnlistedCompanyDomain1RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain1RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain2RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain3RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain4RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain5RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain6RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain7RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain8RUBICON2026-06-30OngoingTaxLitigationsOrDisputesDomain9xbrli:pure544578RUBICONNOTLISTEDINE506V01022RUBICON RESEARCH LIMITED2026-04-012027-03-31Quarterly2026-06-30EquitytruetruetruefalseDuring the quarter ended June 30, 2026, there is no imposition of fine or penalty levied on the company.truetrueTop 1000 listed entitiestruecomr07665OriginaltruefalseMrsPratibha Sudhir Pilgaonkar******00401516Executive DirectorNot ApplicableMD1954-06-12falseActiveNA2000-06-011000MrParag Suganchand Sancheti******07686819Executive DirectorNot ApplicableCEO1983-10-16falseActiveNA2017-01-271010MrVarun Talukdar******08312687Non-Executive - Non Independent DirectorNot Applicable1984-05-18falseActiveNA2023-09-051010MrShantanu Rasgoti******06732021Non-Executive - Non Independent DirectorNot Applicable1979-03-26falseActiveNA2019-04-033010MrCHANGAVALLI VENKAT******02391159Non-Executive - Independent DirectorChairperson1953-09-25falseActiveNA2024-06-112024-06-1124.21110MrKumarapuram Gopalakrishnan Ananthakrishnan******00019325Non-Executive - Independent DirectorNot Applicable1957-02-10falseActiveNA2024-06-112024-06-1124.23342MrMilind Anil Patil******02546815Non-Executive - Independent DirectorNot Applicable1963-11-01falseActiveNA2024-07-102024-07-1023.212221MrsPradnya Nandakumar Saravade******08472973Non-Executive - Independent DirectorNot Applicable1954-06-18falseActiveNA2026-02-032026-02-034.281120truetruetruetruetrueAudit Committee02546815Milind Anil PatilNon-Executive - Independent DirectorChairperson2024-07-24Audit Committee02391159CHANGAVALLI VENKATNon-Executive - Independent DirectorMember2024-07-24Audit Committee08312687Varun TalukdarNon-Executive - Non Independent DirectorMember2026-05-29Audit Committee06732021Shantanu RasgotiNon-Executive - Non Independent DirectorMember2024-07-242026-05-29Nomination and remuneration committee00019325Kumarapuram Gopalakrishnan AnanthakrishnanNon-Executive - Independent DirectorChairperson2024-07-24Nomination and remuneration committee06732021Shantanu RasgotiNon-Executive - Non Independent DirectorMember2024-07-24Nomination and remuneration committee02391159CHANGAVALLI VENKATNon-Executive - Independent DirectorMember2024-07-24Stakeholders Relationship Committee00019325Kumarapuram Gopalakrishnan AnanthakrishnanNon-Executive - Independent DirectorChairperson2024-07-24Stakeholders Relationship Committee06732021Shantanu RasgotiNon-Executive - Non Independent DirectorMember2024-07-24Stakeholders Relationship Committee07686819Parag Suganchand SanchetiExecutive DirectorMember2024-07-24Stakeholders Relationship Committee08472973Pradnya Nandakumar SaravadeNon-Executive - Independent DirectorMember2026-02-03Risk Management Committee07686819Parag Suganchand SanchetiExecutive DirectorChairperson2024-07-24Risk Management Committee02546815Milind Anil PatilNon-Executive -Independent DirectorMember2024-07-24Risk Management Committee08312687Varun TalukdarNon-Executive -Non Independent DirectorMember2024-07-24Corporate Social Responsibility Committee00401516Pratibha Sudhir PilgaonkarExecutive DirectorChairperson2014-12-27Corporate Social Responsibility Committee07686819Parag Suganchand SanchetiExecutive DirectorMember2017-02-21Corporate Social Responsibility Committee02391159CHANGAVALLI VENKATNon-Executive - Independent DirectorMember2024-07-24Corporate Social Responsibility Committee08472973Pradnya Nandakumar SaravadeNon-Executive - Independent DirectorMember2026-02-032026-03-31true8732026-04-1413true8522026-05-2944true884Audit Committee2026-03-30true3220Audit Committee2026-05-2858true3320Nomination and remuneration committee2026-03-30true3220Nomination and remuneration committee2026-05-2959true3320Corporate Social Responsibility Committee2026-03-31true4420Corporate Social Responsibility Committee2026-05-2958true4420truetruetruetrueYestruetruetrueMs. Deepashree TanksaleCompany Secretary and Compliance OfficerfalseDeepashree TanksaleCompany Secretary and Compliance OfficerThane2026-07-3003300Arinna Lifesciences Limited2026-04-3000.850.85Office of the assessment unit of Income Tax Department2022-09-26Status as on 31-03-2026: All further information requested during the quarter was provided. As on 31-03-2026 , the matter is pending adjudication before the Commissioner of Income-tax (Appeals) / NFAC . Brief Details of the case were disclosed in the last disclosure.Status as on June 30, 2026: Ongoing. The matter is currently pending.Office of the assessment unit of Income Tax Department2023-07-26Status as on 31-03-2026:The Hon'ble CIT(A) / NFAC, vide order dated 28.03.2026 passed under section 250 of the Income-tax Act, 1961, allowed the appeal. The demand of Rs. 393.6 million arising on account of ICDS adjustment has been fully deleted, and the major issues has been adjudicated in favour of the Assessee. At present, only a minor issue remains, pertaining to interest on late payment of TDS amounting to Rs. 1,710. Brief Details of the case were disclosed in the last disclosure. Status as on June 30, 2026: Only a minor issue remains, pertaining to interest on late payment of TDS amounting to Rs1,710/-.Intimation order u/s 143(1) of the Income Tax Act, 19612023-12-29Status as on 31-03-2026: The Company will contesting the matter in appeal before the appropriate appellate authority against the draft assesssment order received during the quarter under Section 144C(1) of the Income-tax Act, 1961, with an addition of Rs. 206.8 million has been proposed on account of adjustment in the Arm's Length Price (ALP) as suggested by the Transfer Pricing Office Brief Details of the case were disclosed in the last disclosure.Status as on June 30, 2026: Ongoing. The matter is currently pending.Pfizer INC. and Pfizer Ireland Pharmaceuticals2024-05-23Status: Ongoing. The matter is currently pending. Brief Details of the case were disclosed in the last disclosure.Status as on June 30, 2026: Ongoing. The matter is currently pending.Metacel Pharmaceuticals LLC (Counterclaim filed by Rubicon Research Limited2023-08-08Status as on March 31, 2026: Ongoing. The matter is currently pending. Brief Details of the case were disclosed in the last disclosure.Status as on June 30, 2026: Ongoing. The matter is currently pending.Office of Deputy Commissioner of Income Tax, MumbaI2026-01-05Status as on 31-03-2026: AdvaGen Pharma Ltd, USA, a material step down subsidiary company, received a demand notice under section 156 of the Income-Tax Act, 1961 from the office of Deputy Commissioner of Income Tax, Mumbai. The notice specifies the total demand payable including tax and interest of INR 4,18,84,613/- for assessment year 2021-22. This arises from the denial of a DTAA exemption on income of INR 10,03,57,800, following the tax authority's conclusion that the 'Make Available' clause under the India-US DTAA was applicable. Assessment year 2021-22. On 19/01/26, an Appeal has been filed before the Income Tax Appellate Tribunal (ITAT), against the assessment order passed under Section 143(3) read with Section 144C(13) of the Income-tax Act, 1961. As on 31-03-2026, the matter is currently pending.Status as on June 30, 2026: Ongoing. The matter is currently pending.Income Tax Department (Assessment Unit), Mumbai2026-04-21Not ApplicableCoomunication: Assessment Order u/s 143(3) read with section 144C (3) and 144B and Demand Notice u/s 156 of the Income-tax Act, 196.1; Brief Summary: The Company has received an assessment order for AY 2023-24 wherein certain additions/ disallowances amounting to Rs. 20,68,44,914/- with respect to Arms’ Length Pricing adjustment to the international transactions have been made. Total demand raised amounts to Rs. 17,25,17,210/-, subject to outcome of appeal / rectification. Status as on June 30, 2026: Ongoing. Appeal has been filed and the matter is currently pending1. CIT (APPEAL) 2. Circle (1)(1)(1) / Ahmedabad2017-11-17Last Disclosure: Not ApplicableThis case pertains to Arinna Lifesciences Limited, subsidiary of the Company effective 30-04-2026; Brief: Addition of Share Premium amount received from Venture Capital Fund(MOPE) and Promoters U/s 56(2)(viib) Against order U/S 147 r.w.s 144 Dt. 31/03/2022, First notice received 17/11/2017 Notice u/s 142(1) Assessment. (Total Exposure: Rs. 7,70,00,027) Notice issued by Circle (1)(1)(1) / Ahmedabad for similar matter: (a) Penalty for disallowance of Interest on late payment of TDS Notice U/S 274r.w.s 271(1)(c) Dt. 07.09.2023 First Notice Received 17/11/2017 Notice u/s 142(1) Assessment; and (b)Penalty for Addition of Share Premium amount received from Venture Capital Fund ((MOPE) and Promoters U/s 56(2)(viib) Notice U/S 274r.w.s 271(1)(c) Dt. 07.09.2023 First Notice received 17/11/2017 Notice u/s 142(1) Assessment (Exposure: Rs. 8,24,513) Status: As on 30 June 2026 - Awaiting for CIT (Appeal) case result.Circle (1)(1)(1) / Ahmedabad2017-09-04Last Disclosure: Not ApplicableThis case pertains to Arinna Lifesciences Limited, subsidiary of the Company effective 30-04-2026; (a)Addition of Share Premium amount received from Venture Capital Fund (MOPE) U/s 56(2)(viib) Appeal against Order U/s 143(3) Dt.23/12/2018, first Notice received 04/09/2017 Notice u/s 143(2); and (b) Penalty U/S 271(1)(c ) against Addition of Share Premium amount received from Venture Capital Fund (MOPE)U/s 56(2)(viib) First notice received 04/09/2017 Notice u/s 143(2) (Total Exposure: Rs. 10,13,63,004) Status: As on 30 June 2026 - Pending from Authority and Awaiting for CIT (Appeal) case result.